2 recruiting, 1 not yet recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 2 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Jun Huang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM SBRT, PD-1 Antibody, H101 - CRC, Liver Metastasis Colon Cancer | Phase 2 | Not yet recruiting | Jun Huang | 114 | 2026-06-01 | 2026-04-28 |
| SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases Stereotactic body radiation therapy, PD-1 Monoclonal Antibody, Chemotherapy - Colorectal Cancer, Liver Metastases | Phase 3 | Recruiting | Jun Huang | 24 | 2025-04-10 | 2026-06-30 |
| mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody, mFOLFOX6 - Colorectal Cancer (CRC), pMMR/MSS Adenocarcinoma of the Colon or Rectum | Phase 3 | Recruiting | Jun Huang | 166 | 2025-01-18 | 2025-12-24 |
Drug Therapy (2) · Fluorouracil (2) · Radiosurgery (2) · spartalizumab (2) · Bevacizumab (1) · IFL protocol (1) · Irinotecan (1) · Leucovorin (1) · Oncolytic Virotherapy (1) · sintilimab (1)
China (3)